{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T19:40:10Z","timestamp":1745782810104,"version":"3.40.4"},"reference-count":20,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2017,6,27]]},"abstract":"<jats:p>Acquired haemophilia A (AHA) is a bleeding disorder that results from autoantibodies against factor VIII (FVIII). A 70-year-old man with a history of interstitial lung disease presented with spontaneous bleeding into his thigh. He had undetectable FVIII levels and a high-titre FVIII inhibitor (&gt;2000\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u00b0Bethesda units\/mL) and was diagnosed with AHA. He had several relapses, required multiple haemostatic and immunosuppressive treatments but eventually achieved a stable remission after 2\u00c3\u00a2\u00e2\u201a\u00ac\u00e2\u20ac\u00b0years of therapy.<\/jats:p><jats:p>Our patient matches the typical elderly male demographic of AHA. His relapsing course with remarkably high and persistent inhibitor titre highlights the need for close monitoring and aggressive upfront treatment. Whereas cyclophosphamide and steroids are often used first line in AHA, rituximab has also shown efficacy in refractory patients with high inhibitor levels. The FVIII and inhibitor concentration on presentation have been associated with treatment response and may be used as prognostic factors to tailor immunosuppressive regimens.<\/jats:p>","DOI":"10.1136\/bcr-2017-220932","type":"journal-article","created":{"date-parts":[[2017,7,29]],"date-time":"2017-07-29T02:55:18Z","timestamp":1501296918000},"page":"bcr-2017-220932","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Acquired haemophilia A with a recalcitrant high-titre factor VIII inhibitor in the setting of interstitial lung disease"],"prefix":"10.1136","volume":"2017","author":[{"given":"Lova","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David B","family":"Sykes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2017,7,28]]},"reference":[{"key":"2025042712173405000_2017.jul28_1.bcr-2017-220932.1","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1055\/s-0032-1315757","article-title":"Acquired inhibitors of coagulation factors: part I-acquired hemophilia A","volume":"38","author":"Coppola","year":"2012","journal-title":"Semin Thromb Hemost"},{"key":"2025042712173405000_2017.jul28_1.bcr-2017-220932.2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2012.04654.x"},{"key":"2025042712173405000_2017.jul28_1.bcr-2017-220932.3","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/ijlh.12210","article-title":"Acquired hemophilia: a case report and review of the literature","volume":"36","author":"Mulliez","year":"2014","journal-title":"Int J Lab Hematol"},{"key":"2025042712173405000_2017.jul28_1.bcr-2017-220932.4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-143586"},{"key":"2025042712173405000_2017.jul28_1.bcr-2017-220932.5","unstructured":"Mannucci PM , Franchini M . Porcine recombinant factor VIII: an additional weapon to handle anti-factor VIII antibodies. Blood Transfus 2017;15.doi:10.2450\/2016.0030-16"},{"key":"2025042712173405000_2017.jul28_1.bcr-2017-220932.6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/hae.13040","article-title":"Recombinant porcine sequence factor VIII (rpFVIII) for acquired haemophilia A: practical clinical experience of its use in seven patients","volume":"23","author":"Tarantino","year":"2017","journal-title":"Haemophilia"},{"key":"2025042712173405000_2017.jul28_1.bcr-2017-220932.7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-409185"},{"key":"2025042712173405000_2017.jul28_1.bcr-2017-220932.8","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12829"},{"key":"2025042712173405000_2017.jul28_1.bcr-2017-220932.9","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2008.001743"},{"key":"2025042712173405000_2017.jul28_1.bcr-2017-220932.10","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/MBC.0b013e3283646635","article-title":"Acquired hemophilia in the patient suffering from rheumatoid arthritis: case report","volume":"24","author":"Drobiecki","year":"2013","journal-title":"Blood Coagul Fibrinolysis"},{"key":"2025042712173405000_2017.jul28_1.bcr-2017-220932.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2010.11.005"},{"key":"2025042712173405000_2017.jul28_1.bcr-2017-220932.12","doi-asserted-by":"crossref","first-page":"e565","DOI":"10.1111\/hae.13091","article-title":"Acquired autoimmune thrombotic thrombocytopenic purpura in a case of severe haemophilia A","volume":"22","author":"Williams","year":"2016","journal-title":"Haemophilia"},{"key":"2025042712173405000_2017.jul28_1.bcr-2017-220932.13","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jns.2016.08.032","article-title":"Acquired hemophilia A associated with myasthenia gravis and Isaacs' syndrome","volume":"369","author":"Takeda","year":"2016","journal-title":"J Neurol Sci"},{"key":"2025042712173405000_2017.jul28_1.bcr-2017-220932.14","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1390004"},{"key":"2025042712173405000_2017.jul28_1.bcr-2017-220932.15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-587089"},{"key":"2025042712173405000_2017.jul28_1.bcr-2017-220932.16","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0b013e32832ca388"},{"key":"2025042712173405000_2017.jul28_1.bcr-2017-220932.17","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/bjh.12228","article-title":"How I manage patients with acquired haemophilia A","volume":"161","author":"Sborov","year":"2013","journal-title":"Br J Haematol"},{"key":"2025042712173405000_2017.jul28_1.bcr-2017-220932.18","doi-asserted-by":"crossref","unstructured":"McFadyen JD , Tran H , Kaplan ZS . Factor VIII inhibitor eradication with bortezomib in acquired haemophilia A. Br J Haematol 2016. [Epub ahead of print: 19 Jul 2016].doi:10.1111\/bjh.14185","DOI":"10.1111\/bjh.14185"},{"key":"2025042712173405000_2017.jul28_1.bcr-2017-220932.19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-06-029850"},{"key":"2025042712173405000_2017.jul28_1.bcr-2017-220932.20","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04162.x"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2017-220932","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T19:17:40Z","timestamp":1745781460000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2017-220932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,28]]},"references-count":20,"alternative-id":["10.1136\/bcr-2017-220932"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2017-220932","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2017,7,28]]}}}